Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc., shared on X:
“Phase 1 of SYS6010 (EGFR Topo1i ADC) in Chinese patients with NSCLC published today on Cancer Cell.
Some interesting data, lessons learned, and a few open questions!”
Title: SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
Authors: Zi-Ming Li, Zhen Zhou, Zhi-Yong He, Liang Han, Jian Fang, Hong-Mei Sun, Hai-Feng Liu, Ming-Xia Wang, Yi-Bing Liu, Xiu-Juan Qu, Yu Yao, Yi Gong, Yan Yu, Hua-Qiu Shi, Yan Wang, Chun-Xia Su, Kun-Yu Yang, Yan-Hong Shang, Jian Ruan, Xiang-Lin Yuan, Ming-Jun Zhang, Hui Luo, Jiu-Wei Cui, Xiao-Yan Lin, Meng-Xia Li, Hai-Zhou Lou, Run-Xiang Yang, Hao Wu, Xi-Cheng Wang, Mo Dan, Li-Qiong Zhang, Yang-Zhi Su, Xue-Chao Wan, Kai Zou, Ying-Ying Yang, Shun Lu.
Read the full article.
“ADC design and initial data were presented at AACR25!
DXd drug-linker (deruxtecan) vs. JS-1 drug-linker.”
This also can be interesting:
Transformed SCLC in EGFR-Mutant NSCLC: Critical Progress in a High-Risk Setting
